Montreal / April 19, 2024 - NexPlasmaGen is honored to announce that it has won GHP magazine's Best MedTech Oncology Business - Canada 2024 award.
"GHP Magazine's Biotechnology Awards 2024” are designed to recognize and honor the most valuable contributors to the biotechnology industry, as well...
Montreal / April 05, 2024 - NexPlasmaGen is pleased to announce that on February 6, 2024, the 2nd U.S. patent (US 11895763B2) was granted for its medical technology developed for the treatment of breast cancer. NexPlasmaGen has exclusive rights to this patent under license from...
Posted at 17:49h
in
Uncategorized
Montreal / October 06, 2023 - NexPlasmaGen received a financial support of $219,500 from Quebec's Ministère de l'économie, de l'innovation et de l'énergie (MEIE), the National Research Council of Canada (NRC), the Université de Montréal (UdM) and the Mouvement des accélérateurs d'innovation du Québec (MAIN)...
Posted at 16:59h
in
Blog,
Business
Montreal / April 21, 2023 - NexPlasmaGen announces that it has received $511,186 in funding from the ministère de l'économie, de l'innovation et de l’Énergie (MEIE) du Québec and the Québec Breast Cancer Foundation (QBCF) to conduct clinical safety trials with its Convertible Plasma Jet...
NEXPLASMAGEN TO PRESENT AT THE 2023 OBIO INVESTMENT SUMMIT
Canada’s Premier Health Science Investment Event!
Montreal/February 2, 2022 – NexPlasmaGen is proud to announce that it is presenting at 2023 OBIO Investment Summit.
The OBIO Investment Summit will be hosted at the World Trade Centre Toronto on February...
Montreal / July 4, 2022
NexPlasmaGen is a finalist for the ADRIQ Innovation Award 2022 in the category Innovation from Public Research. The Innovation Awards Gala has become a must-attend event in the Quebec ecosystem.
The 32nd ADRIQ Innovation Awards Gala will take place on Thursday, November...